App aims to boost blood sugar control in type 1 diabetes
NCT ID NCT06819306
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a smartphone app called Hedia Diabetes Assistant can help adults with type 1 diabetes keep their blood sugar in a healthy range more often. About 154 people with poorly controlled diabetes will either use the app plus their usual care or just usual care for 6 months. The main goal is to see if the app increases the time blood sugar stays between 70 and 180 mg/dL.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 154 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2025
- Expected to finish
-
May 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Signed informed consent * Aged ≥ 18 years at the time of signing the informed consent * Ability to understand, speak and read French fluently * Diagnosed with type 1 diabetes \> 12 months prior to the day of screening TIR \<70% of last 14 days or HbA1c \>53 mmol/mol (7%) measured within the last month * Subject must have the cognitive and physical skills to use mobile applications * Access to a smartphone with iOS version 16 and up or Android version 12 and up * Treated with the same pen-based insulin regimen with basal insulin (insulin glargine, degludec, or detemir) and rapid-acting insulin (insulin aspart, lispro, glulisine) for at least the three preceding months * rtCGM use ≥ 1 month from screening date with ≥70% measurements for the last ≥ 14 days * Willing to use the same type of CGM for the duration of the clinical investigation * Willing to be telemonitored during the study period * If female participants of childbearing potential; willing to have a pregnancy test performed and to use a highly effective method of contraception * Affiliated to the French social security system Exclusion Criteria: * Use of human insulin or premixed insulin * Using a bolus calculator as a part of standard of care treatment at the time of screening * If the principal investigator deems that subjects are not healthy, not capable of completing the investigation or in other ways deemed unfit for participation in the investigation * Ongoing participation in other interventional clinical trials or investigations during the investigation period if the principal investigator deems this to potentially affect the safety, clinical performance and/or any study outcomes * Female who is pregnant, breast-feeding or intends to be pregnant during the investigation period * Participant under guardianship, conservatorship, safeguard of justice, or any other legal protection measure for a vulnerable adult
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Type 1 diabetes mellitus (T1DM) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Hospitalier Universitaire d'Angers
Angers, France
-
Centre hospitalier universitaire de Nantes
Nantes, France
-
Centre hospitalier universitaire de Nîmes
Nîmes, France
-
Centre hospitalier universitaire de Poitiers
Poitiers, France
-
Hospices Civils de Lyon
Lyon, France
-
Hôpital Bichat - Claude-Bernard
Paris, 75018, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Video game meets glucose monitor: a new way to teach diabetes skills to children
- Could a 3-Step immune therapy save Insulin-Making cells in newly diagnosed type 1 diabetes?
- Study reveals mental health ties to diabetes Self-Care in teens and young adults
- Can a simple monitor improve diabetes care after hospital discharge?
- New app could help kids with diabetes dose insulin safely
- New app aims to prevent dangerous blood sugar dips during workouts for type 1 diabetes